We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers spent more than $68 billion for the top acquisitions in 2022 and the biggest buyout by far was Amgen’s, announced just weeks before the year’s end. Read More
Astellas Pharma, Pfizer’s Medivation subsidiary and Regents of the University of California have filed a lawsuit alleging that Sun Pharmaceutical infringed on a patent for their blockbuster prostate cancer drug Xtandi (enzalutamide). Read More
Gilead Sciences subsidiary Kite Pharma has entered into a purchase deal with Tmunity Therapeutics — the company founded by CAR-T cell pioneer Carl June — gaining access to Tmunity’s “armored” CAR-T cell platform. Read More
Japan’s Takeda is acquiring Nimbus Therapeutics subsidiary Nimbus Lakshmi and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858 in a deal worth up to $6 billion. Read More
In 2021, manufacturers boosted the cost of seven of the country’s most expensive drugs by more than $805 million without any evidence supporting the price hikes, the Institute for Clinical and Evidence Review (ICER) reports in its latest annual cost analysis. Read More
Summit Therapeutics has acquired licensing rights for Akeso’s ivonescimab, an antibody that targets both programmed cell death receptor 1 (PD-1) and vascular endothelial growth factor (VEGF) in patients with nonsmall-cell lung cancer (NCSLC). Read More
Johnson & Johnson (J&J) has sued Amgen for allegedly violating its patent protections for blockbuster Stelara (ustekinumab) — a biologic FDA-approved for treating ulcerative colitis, psoriatic arthritis, plaque psoriasis and Crohn’s disease, among other indications. Read More